News
SimBioSys Presents 9 Applications of TumorScope Platform at AACR 2022
Genoa Ventures and Northpond Ventures co-lead investment in precision medicine platform that develops virtual tumors in 3D to predict response to therapy using standard-of-care data
Biopharma Dealmakers: Virtualizing cancer to eliminate uncertainty and individualize care
No two tumors are alike. What if we could model treatment planning for each individual patient? Meet TumorScope – the first of its kind 4D Tumor Modeling platform that combines state of the art biophysical modeling, spatial profiling, and artificial intelligence to...
Novel Device May Predict Response to Therapy in Patients With Early Breast Cancer
Frederick Howard, MD, a medical oncology fellow in the Department of Medicine at the University of Chicago, discussed the clinical benefits of the SimBioSys TumorScope model for the treatment of early breast cancer in an interview with Targeted Oncology. Even with...
SimBioSys Raises $15 Million Series A to Develop the Future of Precision Cancer Care
Genoa Ventures and Northpond Ventures co-lead investment in precision medicine platform that develops virtual tumors in 3D to predict response to therapy using standard-of-care data
Transforming Cancer Care with Dr. John Cole
John Cole, Co-Founder & Chief Scientific Officer of Research Park startup SimBioSys, joins the podcast! He discusses the breakthroughs his team has created for "transforming decision making and patient experience in cancer care” through a powerful software...
Wired in: Interview with Tushar Pandey
Each week, staff writer Paul Wood interviews a high-tech difference-maker. This week, meet TUSHAR PANDEY, chief executive officer at SimBioSys Inc. in the University of Illinois Research Park. The company is working on technology to allow doctors and scientists to...
Blogs
Highlights from ESMO Breast Cancer 2022
By Dorys Lopez The ESMO Breast Cancer 2022 took place in Berlin on May 3 – 5. A well-attended conference covering a broad range of breast cancer topics. Our team was there to present three posters. Here are our takeaway messages from the conference. Escalation and...
Highlights from AACR2022
By Dorys LopezAfter two consecutive years of virtually holding the annual meeting of the American Association for Cancer Research (AACR), the conference returned to an in-person format, while retaining a hybrid option for those who prefer to join virtually. There were...
Key take home messages from the San Antonio Breast Cancer Symposium 2021
By Dorys Lopez From December 7th -10th the San Antonio Breast Cancer Symposium gathered breast cancer experts from all over the world to share the latest medical and scientific advances in the breast cancer field. Our team attended the meeting to present our research...
Why is it important to raise breast cancer awareness?
By Dorys Lopez Breast cancer is a group of diseases, each one characterized by different molecular features, and each one with different treatment needs. Scientific advances in the field of precision medicine have made it possible to develop targeted therapies and...
Why Cancer? Why Us? Why Now?
By Tushar Pandey, Joseph Peterson, John Cole Most of us have experienced the pain of a friend or family member’s cancer diagnosis and treatment in our lives. The process of diagnosis, treatment and monitoring — and the resulting uncertainty — has a debilitating...
Publications
Using a multimodal approach to elucidate racial disparities in breast cancer biology by integrating tumor imaging and -omics data
Abstract Background: Race-related differences in breast cancer incidence and clinical outcome have been well documented, with many studies focusing on socioeconomic determinants contributing to African American (AA) breast cancer patients having higher mortality...
Multimodal approach to capture spatially resolved single-cell tumor heterogeneity in breast cancer
Abstract Tumor heterogeneity is known to play a key role in drug response and resistance. However, knowledge of tumor heterogeneity is largely limited to genetics and biopsy samples representing one region of the tumor. The study of spatial tumor heterogeneity is...
Novel imaging marker for low- and mid-recurrence score patients at risk for recurrence
Abstract Background: The 21-gene (Oncotype DX) recurrence score (RS) has been utilized as a prognostic assay in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. The results stratify patients into...
Prediction of Response to Neoadjuvant Therapy (NAT) in Early Breast Cancer (EBC) at Community Hospitals – SimBioSys® TumorScope(TM) Validation Study
Abstract While most cancer patients are treated at community hospitals, specialized equipment, diagnostic tests, and therapeutic regimens are generally validated at academic settings. Here we present a novel approach to precision medicine to improve outcomes in breast...
The case for simul-omics: identifying IO biomarkers of Ganitumab-Metformin pathological complete response (pCR)
Abstract Background: During the I-SPY2 clinical trial, ganitumab (G) immunotherapy (IO) was co-administered with metformin (GM) to counteract G-induced hyperglycemia. The GM + standard of care (SOC) combination showed promising results but did not meet the statistical...
Spatially-resolved single-cell HER2 tumor heterogeneity captured by biophysical modeling
Abstract: Breast cancer is a highly heterogeneous disease. Prognosis and treatment are usually decided based on the expression of 3 molecular markers; one being the human epidermal growth factor receptor 2 (HER2). Classification of HER2 tumors generally follows a...
Novel platform combines pathology and transcriptomics for a multi-scale analysis and visualization of the breast tumor heterogeneity
Abstract: Cancer heterogeneity is associated with drug resistance, risk of disease recurrence and metastasis. Pathology allows for the assessment of heterogeneity in the tumor. However, this assessment is limited to an overall assessment of the tumor microenvironment...
Prediction of Response to Neoadjuvant Therapy in Early-Stage Breast Cancer using a Biophysical Simulation Platform
Abstract: With the rapidly changing landscape of early-stage breast cancer, there is a significant need for upfront biomarkers to enable physicians to “right-size” therapy for patients. It is well known that tumor heterogeneity drives the variability of response to...
A multi-scale analysis and visualization platform for cancer data – deriving tumor microenvironment behavior from pathology and transcriptomics
Abstract: Heterogeneity is a hallmark of cancer and perhaps one of the most important features associated with resistance to therapies and likelihood of recurrence and/or metastasis. Genomic instability contributes to genetic diversity, which leads to high levels of...
Accurate modeling of HER2 positive breast cancer disease progression with a biophysical modeling software
Abstract: Breast cancer (BC) progression during NAT is associated with development of distant metastases, positive LN status, and decreased OS/RFS. These can occur in the context of clinical trials and therapy de-escalation, where the focus is on delivering effective...
Whitepapers
Precision Medicine in Breast Cancer
Thank you for your interest in our white paper. Please fill out the form below to be directed to a downloadable version